Q-omics provides the consensus-scored MYPOP profile across patient tissues and cancer cell-line models. MYPOP expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, MYPOP is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, MYPOP RNA expression shows 18,813 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCS, HNSC, and ACC as cancer lineages where MYPOP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYPOP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYPOP survival associations across molecular data types. MYPOP RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYPOP RNA expression–survival associations across cancer types. High MYPOP expression shows unfavorable associations in UCS, KIRC, LIHC, ACC, OV and UVM. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for MYPOP RNA expression.
This table summarizes MYPOP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for MYPOP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYPOP shows higher tumor expression in HNSC, LIHC, LUSC, LUAD, BLCA and COAD. The HNSC box plot shows higher MYPOP RNA expression in tumor versus normal tissue (log2 FC = +0.847, t-test p < 0.001).
This table shows molecular features associated with MYPOP in patient tissues and cancer cell lines. In patient samples, MYPOP shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MYPOP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
